Compare Recursion Pharmaceuticals Inc (RXRX) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Vital Farms Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.86B), while Vital Farms Inc trades at $9.89 (market cap $432.32M). The key difference: Recursion Pharmaceuticals Inc is far larger — about 4.3× Vital Farms Inc's market cap. Which is the better fit depends on your goals.
| RXRX | VITL | |
|---|---|---|
Market Cap | $1.86B | $432.32M |
Sector | Health | Consumer Staples |
52-Week High | $6.79 | $48.56 |
52-Week Low | $2.84 | $8.28 |
Enterprise Value | $1.38B | $519.33M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Vital Farms (VITL) trades at $10.08, up 1.61% on the day, but faces bearish technical signals with key support at $9. The company reported a challenging Q2 2026 with a net loss per share of $0.47, though revenue of $166 million slightly beat expectations. Gross margin collapsed to 6.6% amid industry oversupply, but management reaffirmed full-year guidance and secured a $125 million term loan for stability.
The outlook is cautious; analyst consensus is a Buy with a $13.00 price target, but near-term risks include persistent margin pressure, cash burn, and competitive pricing gaps. Long-term recovery depends on execution against guidance and market stabilization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
